Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
21Capecitabine+ bevacizumab+ oxaliplatin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1Capecitabine + bevacizumab + oxaliplatin + cetuximab | EXPERIMENTAL | - |
| 21Capecitabine + bevacizumab + oxaliplatin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 21Capecitabine + bevacizumab + oxaliplatin | DRUG | 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1. |
| 1Capecitabine + oxaliplatin + bevacizumab + cetuximab | DRUG | 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2). |
Inclusion Criteria: Histology and Staging Disease * Histologically proven advanced colorectal cancer (CRC); not amenable to curative surgery * Of Note: In case of a single metastasis, histological or cytological proof of colorectal carcinoma should be obtained prior to randomisation. * Unidimensio...
Top 20 of 77 competitors
21Capecitabine+ bevacizumab+ oxaliplatin is a combination regimen being studied for the treatment of Colorectal Cancer. It is an investigational combination of capecitabine, bevacizumab, and oxaliplatin, developed by Sanofi. The regimen is currently in Phase 3 clinical development for this indication.
Sanofi (ticker: SNY) is the developer of 21Capecitabine+ bevacizumab+ oxaliplatin. The company is conducting clinical research on this combination regimen for the treatment of Colorectal Cancer. The regimen is currently in Phase 3 development.
21Capecitabine+ bevacizumab+ oxaliplatin is in Phase 3 clinical development for Colorectal Cancer. It is an investigational combination regimen and has not been approved by regulatory authorities. One Phase 3 trial has been completed, with a total enrollment of 750 participants.
21Capecitabine+ bevacizumab+ oxaliplatin has one completed Phase 3 trial, NCT00208546, titled 'Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer'. This trial enrolled 750 participants with Colorectal Cancer and was conducted in the Netherlands. The trial was randomized and active-controlled.
21Capecitabine+ bevacizumab+ oxaliplatin is a combination regimen that includes capecitabine, bevacizumab, and oxaliplatin. The name indicates the combination of these three drugs. It is being studied as a treatment for Colorectal Cancer and is currently in Phase 3 clinical development by Sanofi.